Home/Publication/Qiming & K2VC Double Down on Immunotherapy
Qiming & K2VC Double Down on Immunotherapy 

02 Jun 2023

US$ 19.00

Qiming Venture Partners (Qiming) has led and made a follow-on investment in the pre-series A plus funding round of LTZ T...

Price / article: US$19.00
OR existing subscriber
Related Publications

Listen to Australia/New Zealand Investments (Subscribers' Weekly 20 Nov 2026)...

Listen to Australia/New Zealand Divestments (Subscribers' Weekly 20 Nov 2026)...

Connect With Us

We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.

Rest assured that your email address will not be shared, as we hate spams as much as you do.